Roche Pharmaceuticals to help with digestive tract oncology drug innovation, for China's recruitment partners, will provide funding, drug and research and development support

(Shanghai, July 6, 2020) Today, Roche Pharmaceuticals China announced that in order to meet the outstanding needs of china'sdigestivetumor patients, and promote the innovation of China'sdigestivetumor drugs, Roche will officially launch a special project for China's "DigestionImmuno
Joint Treatment Cooperation Program" (the "Cooperative Special Program"), which will support innovative Chinese enterprises in the development of new research and development of new research and development of non-monetary drugsthe incidence of gastrointestinal tumors in China accounted for about 40% of the overall incidence of tumors, significantly higher than the world average, many digestive tract tumors in China accounted for more than 50% of the total number of cases, such as liver cancer, esophageal cancer,stomach cancerIn addition, China's annual deaths due to digestive tract tumors accounted for 50% of the annual number of cancer deaths, the overall five-year survival rate of most patients with digestive tract tumors is less than 20%, such as China's stomach cancer 5-year survival rate of 20%, liver cancer 5-year survival rate of 12.5%, esophageal cancer 5-year survival rate of 15%, andpancreatic cancer5-year survival rate of only 7.2%" Roche has been investing in the field of digestive tract tumors and has been actively bringing a variety of innovative drugs to the digestive tract tumor to ChinaIn the face of the unfinished demands of the vast number of Chinese digestive tumor patients, we look forward to supporting China to achieve more, faster and better breakthroughs in the field of digestive tumor treatment through this special cooperation programPeter Ahnesorg, head of global digestive oncology at Roche Pharmaceuticals, said the "Roche Digestive Tract Tumor Immuno
Joint Treatment Cooperation Program" will be open to all Chinese innovative pharmaceutical enterprises within 5 years, specific support methods include, but not limited to, to the Chinese pharmaceutical companies to provide the Roche cancer immune products Tai Sanqi ® (Atilizhu monotagagain) and the target drug Avetin ® (Bevalju monotonica) research drugs, through joint research with domestic innovative pharmaceutical companies The program will also provide research and development funding on the basis of mutual agreement, and roche pharmaceuticals will also provide scientific and research support to innovative pharmaceutical companies in China in the course of the partnership to help them optimize their strategies and accelerate the research and development process "With China's inclusion of biomedicine as a strategic industry and strong support from the Chinese government for pharmaceutical innovation, China is becoming a hot bed of global pharmaceutical innovation, with china's global contribution to the number of new drugs developed reaching 7.8%," said Zhou Hong
, president of Roche Pharmaceuticals china, Roche Pharmaceuticals has long been rooted in China and actively explores cooperation with all parties, and the launch of this special program will also open the door to extensive cooperation between Roche and Chinese research institutions and local innovative enterprises "
"Roche Digestive Tract Tumor Immunotherapy Joint Treatment Co-operation Program" partner open application for all Chinese innovative pharmaceutical enterprises
cooperation scope / requirements: 1 Innovative molecules, innovative targets or innovative technologies 2 The mechanism of action is clear
clear
of property rights/patents
4 The scientific basis of the drug joint is reasonable
5 The product has not yet been listed cooperation mode: 1 China's innovative pharmaceutical enterprises to submit the necessary pre-
and provide the necessary pre-
2 The Roche pharmaceutical team to assess the feasible
the two sides to enter into a cooperation
agreement
china .
collaboration@roche.com and about Roche's in the field of digestive tract oncology
as a leader in individualized medicine, Roche has been investing in the field of digestive tract oncology for a long time to develop innovative drugs and is actively bringing innovative drugs to China At present, Roche for stomach cancer, colorectal cancer of Theroda ® (Kapetabin), Anvitin ® (Bevalzhu monotagatisism), Herceptin ® (qutozhu monotagatist) and other drugs have benefited tens of thousands of Chinese digestive tract tumor patients, tumor immune products Tai Sanqi ® (Atiliju monotag) joint Anvitod ® in (BebethaZumab) treatment In addition, Roche has conducted large-scale and innovative drug development in the field of digestive tumors such as colorectal cancer, esophageal cancer and bile duct cancer on the Tasanchi ® atlizumab is a monoclonal antibody designed to bind directly to PD-L1 ligand proteins expressed on tumor cells and tumor-immersed immune cells, blocking its interaction with PD-1 and B7.1 receptors By blocking the PD-L1 pathway, The Tasanchi ® can effectively activate T cells As an innovative cancer immunotherapy, The Tasanchi ® is expected to serve as a base drug for combination therapy, in combination with other immunotherapy, targeted drugs and various chemotherapy drugs for the treatment of a wide range of cancers at present, the ® of Tai Sanqi has been approved in the United States, the European Union and other countries in the world as a single-drug therapy or joint targeted therapy and/or chemotherapy for the treatment of non-small cell lung cancer and small cell lung cancer, specific types of metastatic urinary tract skin cancer and PD-L1 high expression of metastatic triple-negative breast cancer and other types of cancer On February 13, 2020, Tai Sanqi ® combined chemotherapy for first-line treatment of a wide range of small cell lung cancer was approved in China On February 28th, the State Administration of Drug administration, the Administration of drugs, officially awarded the ® of Tai Sanchi, the United Avetin ® , the priority review qualification for the first-line treatment of advanced non-removable hepatocellular carcinoma
on avetin ® anvitin ® is a prescription drug that infusions through an intravenous vein, a biological antibody that binds specifically to VEGF proteins, and VEGF plays an important role in angio genesis and vascular maintenance throughout the life cycle of the tumor, a process known as angiogenesis Anvitin ® interferes with the blood supply to tumors by binding directly to the VEGF protein to prevent interaction with receptors on vascular cells The blood supply of tumors is considered to be the key to the tumor's ability to grow and spread (metastasis) in the body has a solid scientific basis for the ® of the ta-san chi ® united anavetin ® Thai Sanchi ® united an Avetin Together, the two have the potential to improve the body's own immune system against a variety of tumors Anvirtin's anti-angiogenesis can further strengthen the immunotherapy of tasanchi tumors, reduce VEFG-related immunosuppression, and improve The response of T-cells to tumor antigens research on cancer immunotherapy more than 50 years, Roche has been developing innovative drugs that redefine the treatment of cancer Today, we are investing more than ever in developing innovative treatments that help activate patients' own immune systems to fight cancer roche simply accelerates and expands the clinical benefits of applying The Tasanchi ® to a wider range of cancer patients by designing a framework for the cancer immune cycle and conducting pioneering research in the field of tumor immunoanalysis within the framework Our cancer immunotherapy research uses a comprehensive approach to achieve the goal of rebuilding immunity against tumors to improve patient prognosis roche group
Roche is a global leader in pharmaceutical and diagnostic , committed to advancing science and improving human life Combining the unique advantages of the pharmaceutical and diagnostic businesses makes Roche a leader in individualized medicine, providing the most targeted treatment options for every patient through personalized care Roche is the world's largest biotech company and has a leading differentiated drug in the fields of cancer, immunity, infection
diseases, ophthalmology and central nervous system diseases Roche is a global leader in in vitro diagnostics and tissue-based oncology diagnostics and a pioneer in diabetes management Since its founding in 1896, Roche has been continuously exploring better disease prevention, , diagnosis and treatment programs, and continues to contribute to society At the same time, the company works closely with relevant stakeholders to improve patient access to innovative drugs In the WHO's Essential Medicines catalog, there are more than 30 medicines developed by Roche, including life-saving antibiotics
, antimalarials and anti-tumor drugs Furthermore, Roche has been one of the most sustainable companies in the Dow Jones Sustainability Index (DJSI) pharmaceutical industry for 11 consecutive years Headquartered in Basel, Switzerland, the roche group
is headquartered in Basel, Switzerland, with operations in more than 100 countries and with more than 98,000 global employees in 2019 In 2019, Roche invested 11.7 billion Swiss francs in research and development, with total sales of CHF 61.5 billion Genentech is a wholly owned subsidiary of Roche, which is also a controlling subsidiary of Chugai, Japan's Sinopharmaceutical Corporation For more information, please visit about Roche's China Roche's ties to China date back to the 1920s and 1930s, when Roche began selling its drugs in Shanghai In 1994, Shanghai Roche Pharmaceutical Co., Ltd was officially established in Zhangjiang, Shanghai, becoming the first multinational company to enter Zhangjiang Hi-Tech Park In 2004, Roche Research and Development (China) Co., Ltd was established as the first multinational pharmaceutical company to set up a wholly-owned research and development center in Shanghai, and in 2007, Roche's Global Drug Development Shanghai Center was established to promote and accelerate the clinical development and registration of Roche's innovative drugs in China In 2009, the center joined Roche's Global Drug Development Center and became one of its five drug development centers worldwide in large multinational pharmaceutical companies, Roche has taken the lead in building a complete pharmaceutical value industry chain, including research, development, production, marketing, etc., to provide Chinese patients with anti-tumor, anti-infection and antiviral, transplantation, rheumatism immunity and other key therapeutic fields of breakthrough drugs Currently, Roche has 22 products in China, covering 8 therapeutic areas based in China for the benefit of China and the world: Roche continues to invest more in China, especially in research and development innovation In 2015, Roche invested 863 million yuan to build the new Roche Shanghai Innovation Center, which was officially completed in 2019 The new Innovation Center focuses on research and early development of innovative drugs in the fields of immunity, inflammation and anti-infective diseases In the future, it will effectively promote Roche's collaboration with local research institutions and continue to develop innovative drugs for patients in China and around the world In addition, the Innovation Center is equipped with world-class research facilities to attract the influx of top innovative pharmaceutical talent at home and abroad With a commitment to "first patient needs", Shanghai is Roche's third-largest global strategic center after San Francisco and Basel With the deepening of reform and opening-up, the Chinese government has launched a series of new measures to reform health care, especially in accelerating the registration and approval process for new drugs and updating the national health insurance catalogue At present, Roche has a total of seven targeted drugs - Herceptin ® , Anvitin ® , Trokai ® , Zobovo ® , Ansa ® , Patet ® , Merro ® and a biological agent - Amero ® are included in the National Health Insurance List, benefiting Chinese patients This not only greatly reduces the financial burden of cancer patients, but also promotes the standardized development of the field of cancer treatment in China Roche will actively work with governments, medical institutions and non-governmental organizations to explore innovative cooperation models to benefit more Chinese patients through a series of influential and sustainable initiatives more information about Roche Pharmaceuticals China, please visit Roche China website Source: MedSci Original